Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma.
The antitumor agent phyllanthoside is rapidly metabolized in vitro by mouse plasma. This metabolite has now been isolated from mouse plasma and its structural properties and cytotoxicity characterized. The isolated metabolite was estimated to be greater than 98% pure by HPLC analysis. Mass spectral analysis (fast atom bombardment and tandem mass spectrometry) indicated that the metabolite was the aglycone of phyllanthoside that resulted from the cleavage of the ester bond linking the aglycone and the disaccharide moieties of phyllanthoside. This identification was based on identical collision-induced dissociation spectra of both phyllanthoside and the metabolite. The aglycone was not formed by mouse plasma that had been boiled, filtered to remove proteins, or treated with 1.0 mM diisopropyl fluorophosphate. These results suggest that aglycone formation occurs as a result of plasma esterase activity. Michaelis-Menten constants, Vmax and Km, for conversion of phyllanthoside to the aglycone at 22 degrees C were estimated to be 1.1 mmol/ml plasma/min and 2.0 mM, respectively. Concentrations of phyllanthoside and metabolite required to inhibit cell-colony formation by human A204 rhabdomyosarcoma in vitro were 0.47 nM and 24 microM, respectively. The toxicity of phyllanthoside, and perhaps its efficacy as an antitumor agent in mice, may depend on its rate of conversion to the aglycone.
Chapman
D E
DE
Department of Pharmacology, Mayo Clinic and Foundation, Rochester, MN 55905.
Moore
D J
DJ
Melder
D C
DC
Breau
A
A
Powis
G
G
D000818:Animals; D001572:Benzofurans; D002460:Cell Line / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D004354:Drug Screening Assays, Antitumor; D006027:Glycosides / Q000097:blood / Q000302:isolation & purification* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D008815:Mice, Inbred Strains; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012717:Sesquiterpenes; D013141:Spiro Compounds; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014410:Tumor Stem Cell Assay
D001572:Benzofurans; D006027:Glycosides; D012717:Sesquiterpenes; D013141:Spiro Compounds; C014754:phyllanthoside